ProMIS Neurosciences Inc PMN

Biogen Phase 1

[TopBroker]

Mar. 20, 2015 — March 20, 2015, 8:54 AM PDT ... Biogen Idec stock has reached new highs and added $40 billion to the company's market cap.

For those of you who do not follow the markets. Biogen on the day they announced the results from their phase one adunucanumab antibody , their market cap increased by 40 Billion dollars during the trading day.

[Gbathat]

Thanks TB.  Given the slightly more competitive landscape these days, I'd be good with a meager $10B, lol. Hopefully PMN's idea to collect biomarker data during Phase I could support the best-in-class hypothesis and chum the waters.  Just demonstrating fewer ARIA E side effects at much higher doses would also be a big selling point.  Exciting times ahead. 

[JackRedwood]

At 430 Mil Shares outstanding and if you want a 10 Bil Cap the SP would have to be at $23.00 CAD

[DavidKingCanada]

At 23 per Share, I'd retire and have over 10 Mil in the Bank Not happening with PMN, chances are more for a Buyout before the SP ever goes above a Dollar.

[Fryinpan]

Phase one actually ended in 2012. Phase 1b ended in March 2015.  "Biogen brought aducanumab to a phase 1 trial in 2011 whereby giving a single ascending dose by intravenous infusion to participants with mild-to-moderate AD demonstrated a good safety profile when compared to those receiving the placebo dose. Biogen next conducted a phase 1b randomized, double-blind, placebo